Menu
Disrupting cancer through SurVaxM immunotherapy
At MimiVax, our mission is to disrupt cancer. We are dedicated to improving survival and sending hope to cancer patients
News and Events
“Phase IIa Study of SurVaxM plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma”
“Developing a new cancer immunotherapy, SurVaxM from bench to bedside”
- The U.S. Food and Drug Administration (FDA) has granted supplemental orphan-drug designation (ODD) to SurVaxM for use in patients with malignant gliomas.
- New orphan designation broadens the patient population for potential use of SurVaxM to include forms of adult and pediatric malignant gliomas other than glioblastoma.
- ODD expands market exclusivity of SurVaxM beyond its previous designation of adult glioblastoma.
May 30, 2024
MimiVax announced today that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MimiVax’s SurVaxM vaccine being studied for the treatment of newly diagnosed glioblastoma (nGBM).
“The receipt of Fast Track Designation affirms the importance of new clinical developments of novel therapies to improve the treatment and outcomes for patients with newly diagnosed glioblastoma,” said Michael Ciesielski, CEO of MimiVax. “This designation is a key component in our journey to help patients with glioblastoma to live longer.”
- Enhanced access to the FDA including opportunities for more frequent meetings and direct consultation .
- Drugs with FTD are eligible to apply for Accelerated Approval and Priority Review at the time of a New Drug Application (NDA) submission.
- FTD also allows for a ‘rolling review’ in which MimiVax may submit completed sections of the SurVaxM NDA as they become available, rather than at the end development.
October 12, 2023
The current study found that 51% of nGBM patients receiving SurVaxM had survived at least 2 years and 41% had survived 3 years, considerably higher rates than has been seen historically from standard care.
MimiVax is pleased to announce the published manuscript of the now completed Phase 2A study of SurVaxM, a cancer vaccine, in newly diagnosed glioblastoma (nGBM) in the Journal of Clinical Oncology, authored by researchers from several prominent US cancer centers.
A follow-up Randomized, Blinded Placebo-Controlled Phase 2B Clinical trial of SurVaxM for nGBM (SURVIVE) [NCT05163080] is now recruiting at 10 cancer centers
across the USA.
across the USA.
Manuscript available at:
JCO.22.00996
JCO.22.00996
December 15, 2022
Please help support the 2024 Empire State Ride & Team Danielle (Devlin) Casucci!
This year’s Empire State Ride marks a milestone as it is the ride’s 10-year anniversary, 9 years of which our own VP of Clinical Operations, Danielle Casucci has participated. Danielle and the team will ride bicycles 500+ miles from New York City to Niagara Falls, over the course of a week, to raise money for cancer research at Roswell Park, specifically designated toward the SurVaxM trial.
Previous
Next
MimiVax
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates
PartnerING
MimiVax is improving outcomes and quality of life for those suffering from devastating diseases as well as strengthening the biomedical startup ecosystem of Buffalo, New York.
Pipeline
We’re exploring new ways of stimulating the immune system to fight cancer cells leveraging our proprietary survivin-targeting technology.
Clinical Trials
SurVaxM is presently being studied in glioblastoma (newly diagnosed and recurrent), multiple myeloma and neuroendocrine tumors (NET).
OUR MISSION
To disrupt cancer with innovative immunotherapies
SurVaxM is currently being evaluated in:
-Phase 2b: adult newly diagnosed glioblastoma
-Phase 1: SurVaxM + lenalidomide in multiple myeloma
-Phase 1: Metastatic NeuroEndocrine Tumors (NET)
-Phase 1: Pediatric relapsed/recurrent high grade gliom
Clinical trials
0
Disease Indications
0
Patient Participants
205
Doses
1495
Disrupt cancer with the development of highly innovative immunotherapies
Partner with us
MimiVax is a privately held, clinical-stage biotechnology company that was formed in 2012 from Roswell Park Comprehensive Cancer Center. This was quickly followed by a prestigious award from the American Cancer Society, and support from the Roswell Park Alliance Foundation enabling clinical studies of SurVaxM for glioblastoma. If you are an investor interested in MimiVax, please reach out via the contact form below.
Contact us
To view a listing of investigational clinical trials open to patient enrollment that include SurVaxM, please visit clinicaltrials.gov.
For general inquiries: [email protected]
Help accelerate the pace of SurvaxM clinical trials
The Roswell Park Alliance Foundation is the charitable arm of Roswell Park Comprehensive Cancer Center, where SurVaxM research started. Donations to the Alliance Foundation helped make early phase SurVaxM clinical studies possible and will continue to accelerate the pace and scope of future SurVaxM clinical trials. Please follow this link to make a potentially life changing contribution to this critical effort.